CAMBRIDGE, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced
the pricing of its public offering of 5,000,000 shares of common stock at a public offering price of $23.50 per share. All of the shares are being offered by Beam Therapeutics. In addition, Beam
Therapeutics